JP2021181439A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021181439A5 JP2021181439A5 JP2021109796A JP2021109796A JP2021181439A5 JP 2021181439 A5 JP2021181439 A5 JP 2021181439A5 JP 2021109796 A JP2021109796 A JP 2021109796A JP 2021109796 A JP2021109796 A JP 2021109796A JP 2021181439 A5 JP2021181439 A5 JP 2021181439A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- dose
- pharmaceutical composition
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024161056A JP2024178278A (ja) | 2019-01-11 | 2024-09-18 | 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19151461 | 2019-01-11 | ||
| EP19151461.1 | 2019-01-11 | ||
| JP2020539848A JP2021506953A (ja) | 2019-01-11 | 2020-01-09 | 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539848A Division JP2021506953A (ja) | 2019-01-11 | 2020-01-09 | 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024161056A Division JP2024178278A (ja) | 2019-01-11 | 2024-09-18 | 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021181439A JP2021181439A (ja) | 2021-11-25 |
| JP2021181439A5 true JP2021181439A5 (OSRAM) | 2023-01-18 |
| JP7558900B2 JP7558900B2 (ja) | 2024-10-01 |
Family
ID=65019425
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539848A Pending JP2021506953A (ja) | 2019-01-11 | 2020-01-09 | 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 |
| JP2021109796A Active JP7558900B2 (ja) | 2019-01-11 | 2021-07-01 | 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 |
| JP2024161056A Withdrawn JP2024178278A (ja) | 2019-01-11 | 2024-09-18 | 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539848A Pending JP2021506953A (ja) | 2019-01-11 | 2020-01-09 | 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024161056A Withdrawn JP2024178278A (ja) | 2019-01-11 | 2024-09-18 | 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12435150B2 (OSRAM) |
| EP (1) | EP3908310A1 (OSRAM) |
| JP (3) | JP2021506953A (OSRAM) |
| KR (1) | KR20210114964A (OSRAM) |
| CN (1) | CN113271964A (OSRAM) |
| AU (1) | AU2020205839A1 (OSRAM) |
| BR (1) | BR112021013174A2 (OSRAM) |
| CA (1) | CA3125886A1 (OSRAM) |
| CL (1) | CL2021001829A1 (OSRAM) |
| IL (1) | IL284338A (OSRAM) |
| MX (1) | MX2021008305A (OSRAM) |
| TW (1) | TW202033558A (OSRAM) |
| WO (1) | WO2020144605A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023542678A (ja) * | 2020-09-21 | 2023-10-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 炎症状態の処置のための抗ｃｄ４０抗体の使用。 |
| RS66868B1 (sr) | 2021-01-28 | 2025-06-30 | Regeneron Pharma | Kompozicije i postupci za lečenje sindroma oslobađanja citokina |
| JP2025517363A (ja) * | 2022-05-17 | 2025-06-05 | ザ ユーエービー リサーチ ファンデーション | 炎症性皮膚障害を治療または予防するための方法及び組成物 |
| TW202515607A (zh) * | 2023-06-20 | 2025-04-16 | 英商凱麥博有限公司 | Ox40及ox40l調節劑治療化膿性汗腺炎之用途 |
| WO2025147499A1 (en) * | 2024-01-03 | 2025-07-10 | Abbvie Inc. | Lutikizumab for use in a treatment of hidradenitis suppurativa |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| US20250277048A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025235670A1 (en) | 2024-05-07 | 2025-11-13 | Eledon Pharmaceuticals, Inc. | Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation |
| WO2025235683A1 (en) | 2024-05-07 | 2025-11-13 | Eledon Pharmaceuticals, Inc. | Methods and compositions for prevention of transplant rejection |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US20050136055A1 (en) | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
| KR101223373B1 (ko) | 2003-12-25 | 2013-01-16 | 교와 핫꼬 기린 가부시키가이샤 | 항 ｃｄ４０ 항체의 변이체 |
| EP1854810A1 (en) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
| NZ602020A (en) | 2010-03-31 | 2014-05-30 | Boehringer Ingelheim Int | Anti-cd40 antibodies |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| WO2012121988A2 (en) * | 2011-03-07 | 2012-09-13 | Celgene Corporation | Methods for treating diseases using isoindoline compounds |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| RU2715597C2 (ru) | 2015-05-29 | 2020-03-02 | Эббви Инк. | Антитела к cd40 и способы их применения |
| CN111465399A (zh) | 2017-12-01 | 2020-07-28 | 艾伯维公司 | 抗cd40抗体药物结合物 |
-
2020
- 2020-01-09 CA CA3125886A patent/CA3125886A1/en active Pending
- 2020-01-09 US US17/422,075 patent/US12435150B2/en active Active
- 2020-01-09 TW TW109100800A patent/TW202033558A/zh unknown
- 2020-01-09 JP JP2020539848A patent/JP2021506953A/ja active Pending
- 2020-01-09 BR BR112021013174A patent/BR112021013174A2/pt not_active IP Right Cessation
- 2020-01-09 WO PCT/IB2020/050132 patent/WO2020144605A1/en not_active Ceased
- 2020-01-09 AU AU2020205839A patent/AU2020205839A1/en not_active Abandoned
- 2020-01-09 KR KR1020217024671A patent/KR20210114964A/ko not_active Withdrawn
- 2020-01-09 EP EP20701367.3A patent/EP3908310A1/en active Pending
- 2020-01-09 MX MX2021008305A patent/MX2021008305A/es unknown
- 2020-01-09 CN CN202080008145.XA patent/CN113271964A/zh active Pending
-
2021
- 2021-06-23 IL IL284338A patent/IL284338A/en unknown
- 2021-07-01 JP JP2021109796A patent/JP7558900B2/ja active Active
- 2021-07-08 CL CL2021001829A patent/CL2021001829A1/es unknown
-
2024
- 2024-09-18 JP JP2024161056A patent/JP2024178278A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6537549B2 (en) | Cytokine antagonists for the treatment of localized disorders | |
| JP2021119165A (ja) | Ｉｌ−１７抗体の医薬製品および安定した液体組成物 | |
| US20230303677A1 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists | |
| EP3792281A1 (en) | Methods of treating psoriasis using il-17 antagonists | |
| JP7558900B2 (ja) | 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 | |
| JP2024109762A (ja) | Ｉｌ－１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| US20030185826A1 (en) | Cytokine antagonists for the treatment of localized disorders | |
| Timis et al. | An updated guide in the management of psoriasis for every practitioner | |
| US20230235041A1 (en) | Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists | |
| HK40097110A (en) | Methods of treating plaque psoriasis using il-17 antagonists | |
| CN122070141A (en) | Treatment of hidradenitis suppurativa using anti-BAFF-R antibodies | |
| CA3162052A1 (en) | Methods of treating lichen planus using interleukin-17 (il-17) antagonists | |
| RU2021123408A (ru) | Антитела к cd40 для применения в лечении гнойного гидраденита | |
| Ma et al. | 11 Current Recommendations | |
| Jedrzynski et al. | Biologics for Thyroid Eye Disease | |
| HK40088403A (en) | Methods of treating psoriasis using il-17 antagonists | |
| HK1183673A (en) | Methods of treating psoriasis using il-17 antagonists | |
| HK1183673B (en) | Methods of treating psoriasis using il-17 antagonists |